LOGIN  |  REGISTER
Terns Pharmaceuticals

Grant of Awards to New MultiPlan CEO, Travis Dalton, under NYSE Listing Rules

March 01, 2024 | Last Trade: US$11.01 0.01 -0.09

NEW YORK / Mar 01, 2024 / Business Wire / As required by the rules of the New York Stock Exchange, MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”) today announced that it has granted to Travis Dalton, the Company’s recently appointed President and Chief Executive Officer, on March 1, 2024, employment inducement awards consisting of the following: (i) 6,849,315 with such options vesting over a three-year period from March 1, 2024, in substantially equal annual installments, subject to Mr. Dalton’s continued employment; and (ii) 4,504,504 restricted stock units with such units vesting over a two-year period from March 1, 2024, in substantially equal annual installments, subject to Mr. Dalton’s continued employment. These awards were granted to Mr. Dalton pursuant to the terms of his employment agreement, which was disclosed by the Company on a Form 8-K filed with the SEC on January 4, 2024.

These awards were granted outside the Plan, but except as set forth in the award agreements, will generally be subject to the same terms and conditions as apply to the applicable awards granted under the Company’s 2020 Omnibus Incentive Plan. The Compensation Committee of MultiPlan’s Board of Directors approved these employment inducement awards in reliance on the employment inducement exception to shareholder approval provided under Section 303A.08 of the NYSE Listed Company Manual. To comply with the terms of this exemption, these employment inducement awards require public announcement of the awards and written notice to the NYSE.

About MultiPlan

MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based, and data and decision science services. MultiPlan is a trusted partner to over 700 healthcare payors, brokers, employer groups, and supplemental carriers in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB